Regulatory Press Releases

2022

2022-10-27 08:00 Stille AB: Interim Report Q3 2022 Regulatory MAR
Revenues increased by 17 percent to 59.6 MSEK (51.1). Operating profit increased by 32 percent to 7.2 MSEK (5.5). Positive currency effects of 2.7 MSEK affected the result after financial items. Revenues for Surgical Instruments increased by six percent to 30.1 MSEK (28.4). Profitability was affected by an unfavorable product and geographic market mix. Surgical Table-revenues grew by 30 percent to...
2022-07-15 08:00 Stille AB: Interim Report Q2 2022 Regulatory MAR
Revenues increased by 56 percent to 63.3 MSEK (40.6) and the organic growth amounted to 14 percent with revenues of 46.1 MSEK. Operating profit increased by 72 percent 8.9 MSEK (5.2). Compared to the same quarter last year, business unit Surgical Instruments doubled its revenue driven by the acquired volume of S&T. For the same period, business unit Surgical Tables increased sales by 25 percent...
2022-04-28 08:00 Stille AB: Interim Report Q1 2022 Regulatory MAR
Revenues for the first quarter increased by 72 percent to 61.6 MSEK (35.8) and the organic growth amounted to 21 percent with revenues of 43.3 MSEK. Operating profit increased to 7.5 MSEK (4.0). ”I can conclude that revenues for business unit Surgical Tables never has been higher than during the first quarter 2022. Most notable is the growth outside the US where sales increased by 52 percent...
2022-03-31 08:00 Stille AB: Annual Report 2021 Regulatory
Stille’s Annual Report for the business year of 2021 is being published today and can be found on the company website www.stille.se. The Annual Report 2021 can also be found in full as an attachment to this press release. Torshälla, March 31st, 2022. For more information, please contact: Hanna Ernestam Wilkman CEO and President +46 (0)72 402 10 88 | hanna.e.wilkman@stille.se Stille AB...
2022-02-17 08:00 Stille AB: Year-End Report 2021 Regulatory MAR
Revenues for the fourth quarter reached 59.6 MSEK (45.0), including recently acquired S&T whose sales exceeded expectations. Excluding the acquisition sales amounted to 44.0 MSEK despite challenges in the US for both business units. ”To strengthen growth in the US-market, we have in December launched a new general surgery table, GS2®, in an exclusive collaboration with GE Healthcare...